Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2025-11-17 00:00:00 ET · period of report 2025-11-13 · accession 0001553595-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-17 | 2025-11-13+ | XERS | Shannon John Patrick Jr | See Remarks, Dir | M - OptEx | $1.55 | +96.1K | 2.73M | +4% | +$148.9K |
| D | 2025-11-17 | 2025-11-13 | XERS | Shannon John Patrick Jr | See Remarks, Dir | S - Sale+OE | $7.46 | -23.2K | 2.64M | -0.9% | -$173.4K |
| DM | 2025-11-17 | 2025-11-13+ | XERS | Shannon John Patrick Jr | See Remarks, Dir | M - OptEx | $0.00 | -96.1K | 64.3K | -60% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-13 | M | A | 8,970 | $1.55 | 2,666,395 | D | — | — | |
| 2 | Common | Common Stock | 2025-11-14 | M | A | 87,100 | $1.55 | 2,730,253 | D | — | — | |
| 3 | Common | Common Stock | 2025-11-13 | S | D | 23,242 | $7.46 | 2,643,153 | D | — | — | (F2) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.260 to $7.740, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 4 | Derivative | Stock Option (Right to Buy) | 2025-11-13 | M | D | 8,970 | $0.00 | 151,365 | D | $1.55 · — to 2027-02-03 | 8,970 Common Stock | (F3) The reporting person received the stock options on February 7, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. |
| 5 | Derivative | Stock Option (Right to Buy) | 2025-11-14 | M | D | 87,100 | $0.00 | 64,265 | D | $1.55 · — to 2027-02-03 | 87,100 Common Stock | (F3) The reporting person received the stock options on February 7, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. 25% of the options vested on the first anniversary of the vesting commencement date, and the remaining 75% of options vested in equal monthly installments over the following three (3) years subject to continued employment through such vesting date. |